title: Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al.
authors.forename: Christopher
authors.initials: C
authors.lastname: McCabe
authors.forename: Aki
authors.initials: A
authors.lastname: Tsuchiya
authors.forename: Karl
authors.initials: K
authors.lastname: Claxton
authors.forename: James
authors.initials: J
authors.lastname: Raftery
mesh_terms: D003362:Cost-Benefit Analysis; D005060:Europe; D006291:Health Policy; D006801:Humans; D009965:Orphan Drug Production / Q000191:economics*; D013673:Technology Assessment, Biomedical; D014481:United States